Lannett recalls Niacin Extended-release Tablets, USP, 1,000 mg because they failed dissolution specifications
The recalled 90-count bottles of Niacin Extended-release Tablets, USP, 1,000 mg failed dissolution specifications, and the notice does not say what this could do to a person.
What to do
The notice does not give instructions. Read the official notice for details.
Note from Recalled Today: Don't stop taking a prescribed medicine before you talk to your pharmacist or doctor.
Recall details
- Product
- Niacin Extended-release Tablets, USP, 1,000 mg, Rx Only, 90 Tablets per bottle, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC: 62175-322-46
- Company
- Lannett Company Inc.
- Hazard
- Failed Dissolution Specifications
- Units
- 46,848 90-count bottles
- Where sold
- Nationwide in the USA
- FDA classification
- Class II · Ongoing
- Classified by FDA
- October 22, 2025
- Recall started
- October 10, 2025
- FDA enforcement report
- October 29, 2025
- Identifiers
- Codes: Lot, expiry: 21264027A, Exp 10/30/2025; 22266446A, Exp 12/31/2025; 22266901A, Exp 02/28/2026; 22267553A, 22267554A, Exp 03/31/2026; 22267555A, Exp 02/28/2026; 22267992A, Exp 04/30/2026; 22267993A, 22267994A, Exp 05/31/2026
- FDA recall number: D-0096-2026
The headline, summary and steps above are written in plain English from the official notice below. Identifiers are copied exactly as the agency published them. Always check the official notice before you act.
Official notice
The notice's own wording from FDA.
- Product
- Niacin Extended-release Tablets, USP, 1,000 mg, Rx Only, 90 Tablets per bottle, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC: 62175-322-46
- Reason for recall
- Failed Dissolution Specifications
- Classification
- Class II (Ongoing)
- Distribution
- Nationwide in the USA
- Quantity
- 46,848 90-count bottles
Related recalls
Lannett recalls Niacin Extended-release Tablets 1,000 mg over failed dissolution test
During stability testing, the tablets failed a dissolution test at the 24-hour timepoint, with results coming in too low, so they did not meet the required release specifications.
Lannett Company Inc. · 3984 bottles
Lannett recalls Primidone Tablets USP 250mg over contamination with trace amounts of another ingredient
The active ingredient in these primidone tablets was contaminated with trace amounts of Acemetacin active ingredient, which the notice calls cross contamination with other products.
Lannett Company Inc. · 44865 bottles
Lannett recalls extended-release amphetamine capsules over label mix-up, 1392 bottles
The capsules are labeled as extended-release (ER) but contain only immediate-release (IR) pellets, so the label does not match what is inside.
Lannett Company Inc. · 1392 bottles
Golden State Medical Supply recalls Niacin extended-release 1,000 mg tablets because they failed dissolution testing
The tablets failed dissolution specifications, which means they may not dissolve in the body the way they are meant to, and 24,869 bottles were sold nationwide in the USA.
Golden State Medical Supply Inc. · 24,869 bottles